Cyclacel's cancer drug sapacitabine gets FDA's orphan-drug status

07/1/2010 | Reuters

The FDA granted orphan-drug designation to sapacitabine, Cyclacel Pharmaceuticals' experimental drug for acute myeloid leukemia and bone marrow stem cell disorder. The drugmaker plans to proceed with pivotal late-stage trials of the product this year.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA